3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2/3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
33
Carcinoma, Hepatocellular
27
Neoplasms
19
Colorectal Neoplasms
18
Carcinoma, Non-Small-Cell Lung
16
Stomach Neoplasms
15
Leukemia, Myeloid, Acute
15
Prostatic Neoplasms
12
Lung Neoplasms
12
Colonic Neoplasms
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Rectal Neoplasms
10
Neoplasm Metastasis
8
Leukemia
8
Pancreatic Neoplasms
7
NSCLC
6
Multiple Myeloma
6
Liver Neoplasms
6
Esophageal Neoplasms
6
Glioblastoma
5
Small Cell Lung Carcinoma
4
Recurrence
4
Polycystic Ovary Syndrome
4
Nasopharyngeal Carcinoma
4
Melanoma
4
Lymphoma, Large B-Cell, Diffuse
4
Head and Neck Neoplasms
4
Gestational Trophoblastic Disease
4
Esophageal Squamous Cell Carcinoma
4
Cholangiocarcinoma
4
Interventions
Rituximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Unknown
×
Immunoproliferative Disorders
×
Clear all
NCT01277172
2011-01-14
TREND
Probiomed S.A. de C.V.
Phase 2/3
Unknown
54 enrolled